Harvard Drug Group Memantine Capsules Recall: Failed Dissolution Specifications
Harvard Drug Group recalls 7mg Memantine Hydrochloride Extended-Release capsules due to failed dissolution specifications. This may affect medication effectiveness. Contact for return instructions.
Lower-risk recall
Failed Dissolution Specifications
Contact the company
What happened, in plain English
Harvard Drug Group is recalling 7mg Memantine Hydrochloride Extended-Release capsules because they failed dissolution specifications. This could mean the medication doesn't work as intended, potentially affecting treatment effectiveness. Read more at govinfonow.com/recall/31392-harvard-drug-group-memantine-capsules-recall-failed-dissolution-specifications.
Source Summary by GovInfoNow · govinfonow.com/recall/31392-harvard-drug-group-memantine-capsules-recall-failed-dissolution-specifications · Updated August 17, 2026 · FDA enforcement record: FDA #D-0485-2026
Cite this page
“Harvard Drug Group Memantine Capsules Recall: Failed Dissolution Specifications.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/31392-harvard-drug-group-memantine-capsules-recall-failed-dissolution-specifications. Based on FDA recall #D-0485-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0485-2026%22&limit=1).
Why it’s dangerous
The capsules failed to dissolve properly as intended, which could lead to inconsistent medication levels in the body. This might reduce the effectiveness of the treatment for conditions like Alzheimer's disease.
Who’s affected
People prescribed this medication for conditions like Alzheimer's disease who have the specific lot number N02425. Those using the medication as directed are most at risk.
How to tell if you have this one
Check for the product name 'Memantine Hydrochloride Extended-Release, Capsules, 7 mg, 100 Capsules (10 x 10 blister packs)' with lot number N02425 and expiration date 05/31/2027.
- Brand
Harvard Drug Group- Category
Drug
What to do — step by step
Check Product Details
Verify the lot number and expiration date on the packaging to confirm if the product is affected.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “US Nationwide.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 29 days after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other Harvard Drug Group recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0485-2026 (March 24, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0485-2026 to see it in context.
- Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.